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Abstract

Epstein-Barr virus (EBV) is a human herpesvirus that infects and persists in > 90%
of human adults, generally without causing disease. However, EBV has oncogenic
properties and is associated with several malignancies of epithelial and lymphoid origin.
The details of the molecular steps leading to these different malignancies are poorly
understood. It is believed that some of the EBV latent gene products are involved. Two
small EBV-encoded RNAs, referred to as EBER1 and EBER2 have been shown to be
expressed in all forms of EBV latent infection. These non-polyadenylated and non-protein
coding RNAs are by far the most abundant transcripts expressed in EBV infected cells
(>106 copies), but their function remains unknown. Although, not directly involved in cell
transformation, a number of studies have reported that these RNAs may be involved in
inhibiting apoptosis and providing a proliferative advantage to EBV infected cells. The
molecular mechanisms involved in these processes are unclear. The aim of this study was
to investigate the role of EBER1 in cell proliferation. We prepared stable EBER1
transfectants of different cell types (epithelial, B-cell and T-cell), together with
corresponding control cell lines transfected with the control plasmid only. After
confirming that EBER1 was expressed in all EBER1 transfected cells, we investigated
their proliferative properties using a range of different approaches and methodologies.
Cell proliferation was measured by trypan blue exclusion assay, after subjecting the cells
to either normal growth requirements or serum-deprived condition. ATP activity, as an
indicator of cell proliferation, was measured using Glo-cell viability assay. Soft agar assay
was used to determine the colony forming ability of EBER1 transfected cells. Molecular
mechanism underlying EBER1 induced proliferation was assessed by Real-Time qPCR,
immunocytochemistry and western blot for known proliferation markers, namely Ki67,
PCNA and MCM2. Finally, in an attempt to understand the potential intracellular
pathways that may be activated in EBER1 transfected cells, we examined for the
expression of genes involved in cell proliferation using microarray methodology. The
results from these investigations indicated that EBER1 transfected cells, compared to
controls, had higher ATP activity, proliferated at significantly higher rate, expressed
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higher levels of RNAs and proteins associated with cell proliferation and formed larger
and more colonies in soft agar. Our study also suggested that EBER1 could be inducing
some of these changes by triggering the production of pro-inflammatory cytokines and
anti-apoptotic signals.
Keywords: EBV, Epstein-Barr virus encoded RNA-1 (EBER1), cell proliferation, Ki67,
PCNA, MCM2.
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)Title and Abstract (in Arabic

فهم دور وآليات الحمض النووي الريبي ( )EBER1في تكاثر الخاليا
الملخص

فيروس "ابستين بار" هو الهربس البشري الذي يصيب ويقيم في أكثر من  ٪90من
البشرالبالغين ،وبشكل عام من دون أن يتسبب في أمراض .وبالرغم من ذلك فإن له خصائص
سرطانية ويتشارك مع الكثير من األورام اللمفاوية والظهارية .والتفاصيل الجزيئية المؤدية إلى هذه
األورام ال تزال غير مفهومة بشكل جيد .ويعتقد أن بعض المنتجات في المرحلة الكامنة لفايروس
ابستين تلعب دورا في ذلك .هناك نوعان من الحمضين النووين الريبوزيين ،يطلق عليهما EBER1
و  EBER2ينتجان في كل المراحل الكامنة لفيروس ابستين بار.تعتبر هذه الرناوات الغير مشفرة
وغير المشبعة بالبروتين هي أكثر النسخ وفرة في الخاليا المصابة بفيروس ابستين بار (>106نسخة)
 ،لكن وظائفهم إلى اآلن غير معروفة .على الرغم من عدم مشاركتهم بشكل مباشر في تحول الخاليا،
فقد أفادت عدد من الدراسات أن هذه الرناوات قد تشارك في تثبيط موت الخاليا وتوفير ميزة التكاثر
للخاليا المصابة بفايروس ابستين بار .اآلليات الجزيئية المشاركة في هذه العمليات غير واضحة.
الهدف من هذه البحث هو دراسة دور  EBER1في تكاثر الخاليا .أعددنا أنواع مختلفة من الخاليا
المستقرة (الخاليا الظهارية والخاليا  Bوالخاليا التائية) التي تحتوي على ال  ،EBER1بالمقابل مع
خاليا التحكم التي تحتوي على البالزميد فقط .بعد التأكد من التعبير الجيني لل EBER1في جميع
الخاليا الحاملة ال ، EBER1درسنا خصائص التكاثر باستخدام مجموعة من األساليب والمنهجيات
المختلفة .تم قياس تكاثر الخاليا عن طريق اختبار  ،trypan blueبعد تعريض الخاليا لمتطلبات
النمو الطبيعي أو سيروم منزوع الوسط .تم قياس الطاقة ،كمؤشر على تكاثر الخاليا ،باستخدام Glo-
 .cell viability assayتم استخدام  soft agarلتحديد قدرة الخاليا الحاملة ال  EBER1في
تشكيل مستعمرة .تم تقييم اآللية الجزيئية الكامنة وراء حث  EBER1في التكاثر بواسطة الزمن
الحقيقي لتفاعل البلمرة المتسلسل ،والكيمياء الخلوية المناعية و western blotللدالالت البروتينية
المعروفة ،مثل  Ki67و PCNAو .MCM2في محاولة منا لفهم المسارات المحتملة داخل الخاليا
التي قد يتم تنشيطها في الخاليا التي تحتوي على  ،EBER1درسنا تعبير عن الجينات المشاركة في
تكاثر الخاليا باستخدام تقنية رقائق الحمض النووي الدقيقة .أشارت نتائج هذه الدراسة إلى أن الخاليا
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الحاملة لل ، EBER1مقارنة بالغير الحاملة لهذا الحمض ،كانت ذات طاقة أعلى ،وتكاثرت بمعدل
أعلى ،وعبرت عن مستويات أعلى من األحماض النووية الريبوزية والبروتينات المرتبطة بتكاثر
ضا من هذه
ضا أن  EBER1يمكن أن يحفز بع ً
الخاليا وشكلت مستعمرات أكبر .اقترحت دراستنا أي ً
التغييرات من خالل إطالق  cytokinesالمؤيدة لاللتهابات واإلشارات المضادة لموت الخاليا.
مفاهيم البحث الرئيسية :فيروس ابستين بار ،الحمض النووي الريبي المشفر لفيروس ابستين بار
) ،(EBER1تكاثر الخاليا.MCM2 ،PCNA ،Ki67 ،
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Chapter 1: Introduction
1.1 History and discovery of EBV

Epstein-Barr virus (EBV) was first discovered in 1964 by Anthony Epstein,
Yvonne Barr and Burt Achong by isolating the virus from a Burkitt’s lymphoma (BL)
case. The story began when Burkitt presented a case regarding a jaw lymphoma in a
lecture that took place at Middlesex Hospital Medical School. Among the audience was
Anthony Epstein who was a medical virologist and was working on chicken tumor viruses
(Epstein & Eastwood, 1995). Epstein was fascinated with what he had witnessed and
requested Burkitt for tumor samples so he could focus on the isolation of the agent which
causes Burkitt’s lymphoma (Smith, 2012). However, the virus that was eventually isolated
was not enough to assume that it had a hand in the pathogenesis of BL. Years of further
research and experiments were done before concluding that EBV was indeed involved
(Esau, 2017).

Werner and Gertrude Henle contributed the most in demonstrating and
characterizing the oncogenic potential of EBV. Their seminal experiments showed that
culturing of irradiated BL cells with healthy controlled leukocytes led to hematopoietic
cell proliferation, highlighting the possibility of viral oncogenisis (Henle et al., 1967;
Henle, 1968). They were also a part of the team that first published EBV DNA discovery
from the cells taken from BL biopsies, which proved to be a strong evidence on EBV’s
association with BL (Esau, 2017; zur Hausen et al., 1970).
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1.2 Classification of EBV

EBV is a part of the Herpesviridae family of large DNA viruses. Herpesviridae are
known to infect reptiles, mammals and birds. Viruses in this group are also known to cause
lifelong infections in their host. Only 8 viruses out of 200 belonging to this family are
responsible for causing infections in humans (Arvey et al., 2012). Human herpesviruses
are

classified

into

three

groups:

Alphaherpesvirinae,

Betaherpesvirinae

and

Gammaherpesvirinae. This subdivision is based on biological properties and genomic
sequence of the virus.

The Alpha group is known for having a short reproductive life cycle but spreads
rapidly in its host. Viruses that belong to this group include Varicella-zoster virus (VZV)
and human herpes simplex virus 1 and 2 (HSV-1 and -2). The Beta group however, has a
longer reproductive cycle and grows slowly in host cells. This group consists of human
herpes virus-6A, 6B, and 7 (HHV6 and HHV7) and cytomegalovirus (CMV). The last
group, the Gammaherpes viruses, which include EBV and Human herpesvirus 8 (HHV8) also known as Kaposi’s sarcoma have varying reproducing characteristics and replicate
in plasma and epithelial cells (Ehlers et al., 2010). HHV-8 has been detected in non-AIDSassociated and AIDS-associated Kaposi's sarcoma, some cases from AIDS-associated
multicentric

Castleman's

disease

and

solid

lymphoma,

primary

effusion

lymphoma. Unlike other viruses, HHV-8 encodes several human homologues including
regulatory genes (receptor of G-protein coupled, cyclin D etc) and cytokines (proteins of
macrophage inflammatory, IL-6 and interferon-regulatory factors). These proteins have
important roles in the HHV-8 pathogenesis (Rozen, Sathish, Li, & Yuan, 2008).
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Two types of EBV viruses infect humans; EBV-1 ( also called type A) and EBV2 (called type B) (Walling, Brown, Etienne, Keitel, & Ling, 2003). These two types differ
mainly in their geographic distribution. For instance, EBV-1 is dominant in the developed
Western countries, whilst EBV-2 appears to be common in sub-Saharan Africa (Zimber
et al., 1986). These two strains are observed as super infections in immuno-compromised
patients (Walling et al., 2003). However, it is yet to be confirmed whether both strains can
infect immunocompetent individuals. The reason behind the division of EBV into these
two subtypes was due to certain genetic variations observed in the sequence of EBV
encoded nuclear antigens (EBNAs) (Sample et al., 1990). The two subtypes are further
divided into strains based on the EBV DNA sequence variation (Ruf, Rhyne, Yang,
Cleveland, & Sample, 2000).

1.3 Structure of the viral genome

The EBV genome has a linear double-stranded DNA of ~172 kbp length encoding
for > 85 genes (Fig. 1.1). Open-reading frames (ORFs) are named after the BamH1restriction fragments where they are located. BARF1 ORF, for example, can be located in
the BamHI-A restriction fragment, and is observed extending rightwards (Fig. 1.1).
Several EBV ORFs are organized in two set of genes, lytic or latent genes. Lytic genes
are further divided into immediate early, early and late genes. In EBV, lytic process starts
off by activation of two immediate early viral transcription factors Rta (also named R–
encoded by BRLF1) and Zta (also named EB1, Z, ZEBRA—encoded by BZLF1) (Hong
et al., 2005). Therefore, early gene promoters are activated which play role to express
proteins for viral DNA synthesis (Chevallier-Greco et al., 1986) . Late genes are essential
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for encoding structural proteins (Hong et al., 2005). Furthermore, some latent gene
products are non-translated; including EBV-encoded RNA (EBER)-1 and -2 (Fields et al.,
2007).

There is a string of 0.5-kbp direct terminal repeats in the viral genome, located at
both ends in addition to 6-12 tandem repeats and 3kb internal direct repeats (IRs). These
repeat sequences play a role in the division of the genome into both long and short unique
sequence domains including most of the coding regions (Cheung & Kieff, 1982). These
terminal repeats help in identifying EBV infected cells that are from the same progenitor.
In other words, when a cell is infected with EBV, the viral DNA becomes circular episome
with unique number of terminal repeats undergoing replication, and the new progeny of
EBV would have the same number of terminal repeats as the parental genome (RaabTraub & Flynn, 1986).

5

Figure 1.1: The EBV genome double-stranded DNA. (a) An electron micrograph of
EBV in Burkitt’s lymphoma cell line. (b) Genome of EBV shown as circular double
stranded DNA (~172 kbp long) which is believed to encode >85 genes (c) Open reading
frames for viral latent genes in the EBV genome. The OriP is the site of DNA replication
and episome maintenance. Image adapted from: (Young & Rickinson, 2004).
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1.4 Host range and cell tropism

EBV is ubiquitous and humans are its natural host. However, EBV-like viruses
have been detected in higher primates. Anti-EBV antibodies have been found in many
primate species, which could be due to cross-reactive antibodies existing against their own
species-specific EBV homologues (Kieff et al., 1979). EBV results in a long term infection
in newborn marmosets thus indicating that the response of both humans and marmosets
to EBV infection may be similar (Cox, Chang, Karran, Griffin, & Wedderburn, 1996).

EBV latent infection in lymphocytes can lead to proliferation of the newly infected
cells (Young & Rickinson, 2004). EBV infection in B cells is caused by a certain
interaction of the viral envelope glycoprotein gp350/220 and the cellular receptor of the
c3d complement component, CR2 (CD21) (Fingeroth et al., 1984). Three viral
glycoprotein mechanisms, gp42, gp85 and gp25 mediate the fusion of the envelope with
the host-cell membrane (Li, Turk, & Hutt-Fletcher, 1995). The viral gp42 has the ability
to bind with major histocompatibility complex class II (MHC II), and is used by EBV as
a mediator of B lymphocyte infection (Li et al., 1997). EBV is also believed to have the
ability to infect cells through CD21 independent mechanisms, albeit with a lower
efficiency. Cells that lack CD21 (like epithelial cells) are also thought to be prone to EBV
infection. Furthermore, a virus that lacks gp350/220 may also cause infection (Imai,
Nishikawa, & Takada, 1998). Although EBV is primarily B cell tropic, in some cases it
can infect T lymphocytes, as evident in NK-/T-cell lymphoma (Janz et al., 2000). Studies
have also suggested that the infection in healthy EBV carriers is mainly B cell specific.
However, the virus can also be found in epithelial cells. These cells are thought to have a

7

part in the replication which in turn spreads EBV infection. This has been observed in the
tumors of epithelial origin, such as nasopharyngeal and gastric carcinomas (Kieff, 1979).

The previous studies showed that the glycoprotein gp110 promotes the EBV’s
ability to infect human cells. Moreover, gp110 was shown to play a crucial role in the
infection of B-cells and non-B cells by membrane fusion during the virus entry. Higher
gp110 expression were shown to be more efficient in infecting epithelial or lymphoid
cells (Neuhierl, Feederle, Hammerschmidt, & Delecluse, 2002).

1.5 Viral life cycle and gene expression

1.5.1 EBV life cycle

EBV is a ubiquitous human virus and infects or persists in > 90% of human
throughout their lifetime (Münz & Moormann, 2008), mostly without causing illness.
Because of the lack of empirical evidences, many aspects of EBV life cycle remain
enigmatic. Nonetheless, several models are thought to explain the dynamics of EBV
infection in the normal host. EBV utilizes normal differentiation of B cell physiology and
expresses variety of latent genes to progress from the initial infection to long term
persistence within the memory pool of B cells in the immunocompetent host (ThorleyLawson & Gross, 2004; Thorley-Lawson & Allday, 2008; Young & Rickinson, 2004).

Figure 1.2 shows the interaction taking place between EBV and its host. EBV
spreads through infected saliva, by the Waldeyer tonsillar ring epithelium located in the
oropharynx. One model suggests that lytic infection takes place in epithelial cells resulting
in the release of virus. When EBV infects naïve B cells underlying lymphoid tissues, the

8

virus activates transcription program (latency III). There are several growth program
proteins that appear to regulate the proliferation of the infected cells. This process causes
migration of the infected cells to the follicle initiating germinal center reaction, and
leading to default transcription program (latency II). The default program grants both
survival and recovery signals and leads to exit of the cell from the germinal center as
memory B cell. The latency program (latency 0) comes in the resting memory B cells,
where all viral protein expression is switched off. Occasionally, when these cells divide,
only EBNA1 is expressed (latency I) or else the B cells homeostasis is maintained.

Eventually, after returning back to the tonsil, infected B cells might go through
differentiation into plasma cells. This process triggers viral replication. As a result, the
virus might spread out to other possible hosts through saliva and/ or re-infect B cells within
the same host (Thorley-Lawson & Allday, 2008; Young & Rickinson, 2004). In the case
of primary EBV infection, a strong cellular immune response is provoked which controls
the EBV infection. Thus, in immunocompetent host, a latent-antigen specific T-cell
response eliminates the recently infected cells efficiently. In resting memory B cells,
where there is no viral protein expression, somehow protected or hidden from the immune
system, the virus persists for life in the host (Thorley-Lawson & Allday, 2008; ThorleyLawson & Gross, 2004).

EBV life cycle is similar in all herpesviruses; it consists of a latent state and lytic
stage in which the virus reactivates and replicates. The newly formed viral particle infects
naïve B cell, either in the same host or it could spread to another host. When memory B
cells differentiate to plasma cells upon antigen recognition, then a shift takes place from
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latency to lytic phase (Kapatai & Murray, 2007; Laichalk & Thorley-Lawson, 2005). The
activation of the cellular transcription factor XBP-1 which causes the differentiation,
leads to the activation of EBV ZP promoter resulting in BZLF1 gene transcription, the
master lytic regulator (Thorley-Lawson & Allday, 2008). The only EBV gene that
responds to activation of B cell antigen receptor (BCR) signal transduction pathway is
BZLF1 gene. It also possesses the ability to shift the virus from latency to lytic phase
(Countryman et al., 2009). Upon the activation of the lytic cell, several viral genes
transcription takes place; the genes are classified to immediate early, early and late genes
(Altmann & Hammerschmidt, 2005).
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Figure 1.2: A proposed model for the interaction between the host and EBV in
vivo. a) During primary infection, EBV in saliva reaches the lymphoepithelial
layers of the new host where it is thought to undergo lytic cycle or passes the
epithelial barriers to infect the naïve B cells. This induces the growth program,
in which infected cells differentiate into proliferating B blasts. In the germinal
center of lymph node follicles, B cells differentiate into memory B cells (which
shed the virus from immune system while in the blood circulation. b) During
persistent infection, or latency 0 no viral proteins are expressed except for
EBERs, which are expressed in all latent programs. In order to start the lytic
cycle, infected B cells re-enter the tonsil to differentiate to plasma cells. Image
adapted from: (Young & Rickinson, 2004).
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1.5.2 EBV gene expression

Table 1.1 presents the different EBV transcription programs in infected B cells.
Many factors affect EBV-encoded proteins expression, like the differentiation, the type
and activation status of the infected cell etc. The program of growth-stimulation depends
on the expression of six nuclear and three membrane proteins. Six of them are very
important for proliferation-driving and activation effect of the virus.

EBNA-1 which is a virally encoded protein is essential to maintain the viral
episomes. is expressed in various degrees in cells (Thorley-Lawson, 2005). EBV
expresses two classes of non-coding small RNA (EBER) 1 & 2 in all forms of latency.
They are highly structured RNAs of 167 & 172 nucleotides. EBER 1 & 2 expression is
limited to cell nucleus, they could be found at 107 copies in each cell, in addition to that,
over 22 micro-RNAs are encoded to different degrees in latency, I, II, III (Cai et al., 2006;
Grundhoff et al., 2006).

B cell infection in vitro, has a minimum of six nuclear antigens (EBNAs1, 2, 3A,
3B, 3C and -LP) and three latent membrane proteins (LMPs 1, 2A and 2B). All of these
genes operate in an organized manner to cause the infected cells to go into latent infection,
leading to permanent lymphoblastiod cells lines (LCLs) outgrowth (Fields et al., 2007).
In in vivo, growth-transforming infections of B cells is seen in patients with infectious
mononucleosis, undergoing primary EBV infection, and are moved to the germinal center
(Niedobitek, Young, & Herbst, 1997). Transformation seems to be central to the process
where EBV can colonizes the naïve host. Eventually, T cells surveillance contain these
infected B cell pool. However, that does not occur with some infected cells having down-
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regulated viral gene expression and entering the memory B cell pool as resting cells
(Babcock et al., 2000; Münz & Moormann, 2008).
Table 1.1: The programs of normal B cells with EBV transcription. Adapted from:
(Thorley-Lawson, 2005).
The EBV transcription programs in normal B cells and tumors
Transcription
Genes
Infected
Function
program
expressed
normal Bcell type
Growth
EBNA1, 2, 3a, Naïve.
Activate B cell.
3b, 3c, LP,
LMP1,
LMP2a, and
LMP2b.
Default
EBNA1,
Germinal
Differentiate
LMP1, and
center.
activated B cell
LMP2a.
into memory.
Latency
None.
Peripheral
Allow lifetime
memory.
persistence.
EBNA1 only
EBNA1.
Dividing
Allow virus in
peripheral
latency program
memory.
cell to divide.
Lytic
All lytic genes. Plasma cell. Replicate the virus
in plasma cell.

Infected tumor
type
Immunoblastic
lymphoma.

Hodgkin's
disease (HD).

Burkitt's
lymphoma.

1.5.3 Viral gene expression in EBV- associated malignancies

The different viral gene expression programs have been seen in several human
tumors, including Burkitt’s lymphoma, immunoblastic lymphoma in immunocompromised patients, nasopharyngeal carcinoma and Hodgkin disease (Münz &
Moormann, 2008). These tumors are believed to have arisen originally from certain stages
during EBV life cycle, and are somehow linked to disorders of the immune system
(Fig. 1.2) (Thorley-Lawson, 2005). Burkitt’s lymphoma for example, expresses EBV
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latency I program. Hodgkin disease, T-cell non-Hodgkin lymphoma, nasopharyngeal
carcinoma and gastric carcinoma express type II latency. Type III latency has been seen
mostly in immuno-compromised people and in HIV-associated lymphoproliferative
disorders (Cesarman & Mesri, 1999; Kis, Takahara, Nagy, Klein, & Klein, 2006).

1.6 Epidemiology of EBV infection

1.6.1 Prevalence and geographic distribution

During the 1970s, IARC demonstrated the probability of more than 90% of adults
worldwide infected with EBV, based on detecting antibodies against EBV, specifically
antibodies to complement-fixing soluble (CF/S) antigens and viral capsid antigen (VCA)
(de-The, Lavoue, & Muenz, 1978). It has been proven by many epidemiological studies
the high prevalence of EBV worldwide (Black, Woodall, Evans, Liebhaber, & Henle,
1970; Tischendorf et al., 1970). The age at which the primary infection occurs differs
globally, and the exposure to the virus is most likely because of socioeconomic factors
(Evans, 1971) such as overcrowded places and poor living conditions where sanitation
does not meet the required standards (de-Thé et al., 1975).

EBV is divided to two major types: EBV1 and EBV2, which vary geographically.
The effect of EBV types in the development of different cancers is not known. Usually
patient that are immuno-compromised, harbor both types of EBV (Borisch et al., 1992).
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1.6.2 Transmission and outcome of primary infection

As mentioned before, young individuals are usually most susceptible to EBV,
especially those from poor socioeconomic background, large families, and having poor
hygienic lifestyle. Most of these individuals will become virus carriers by their early
childhood. The virus infects primarily through oral transfer, but can also be transmitted
by blood transfusion. In the developed countries, however, the infection usually occurs
later in life, like in adolescence. Intimate act of exposure may be the primary cause in its
transmission (Hjalgrim, Friborg, & Melbye, 2007). An estimated 50% of primary EBV
infection during adolescence causes clinical infectious mononucleosis. The majority of
individuals in Europe and the US also get infected with EBV at young age, but the one
third, whose infection is delayed into adolescents are at increased risk for infectious
mononucleosis (Balfour et al., 2013).

Following primary infection, EBV infected B cells circulates and stay undetected
for life in a latent state (Thorley-Lawson & Gross, 2004; Young & Rickinson, 2004).
Mucosal epithelial cells are also prone to EBV infection through intermittent replication
of viral productivity (Frangou, Buettner, & Niedobitek, 2005). Resting memory B cells
are considered as the true reservoir of the latent virus in healthy carriers (Table1.1). A
restricted pattern of the viral gene expression occurs in these cells (Miyashita et al., 1994),
which helps infected cells to persist in the face of an efficient cytotoxic T lymphocyte
surveillance (CTL) (Masucci & Ernberg, 1994).
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1.7 EBV associated diseases

EBV is one of the most successfully transforming virus that cause infections in 9095% of people worldwide. However, the development of the diseases associated with EBV
are considered rare (Khan & Hashim, 2014). There are several human malignancies that
are linked to EBV, which are of epithelial and lymphoid origin (Griffin, 1998) including,
Burkitt’s lymphoma (BL) (Schmitz et al., 2012), post-transplant lymphoproliferative
disease (PTLD) (Gottschalk, Rooney, & Heslop, 2005), Hodgkin’s lymphoma (HL)
(Vockerodt, Cader, Shannon-Lowe, & Murray, 2014) and X-linked lymphoproliferative
disease (Marsh & Filipovich, 2011). Some of the epithelial malignancies that are
associated with EBV include, nasopharyngeal carcinoma (NPC) (Lin et al., 2014) and
gastric carcinoma (GC) (Iizasa, Nanbo, Nishikawa, Jinushi, & Yoshiyama, 2012). In
addition to malignancies, EBV has been linked to several autoimmune diseases like
multiple sclerosis (MS) (Hassani et al., 2018; Lünemann & Münz, 2007) and systemic
lupus erythematosus (SLE) (Ascherio & Munger, 2015; Münz et al., 2008).
1.8 The lymphoblastoid cell line – an in vitro model of EBV infection and
transformation

Lymphoblastoid cell lines (LCLs) are peripheral blood cells which when
infected with EBV results in spontaneous outgrowth of EBV transformed cell lines
(Rickinson et al., 1984). LCLs are produced when B cells are infected with EBV which
produces immortalized cell line with individual genotype useful for genetic studies.
Multiple copies of viral episomes in each cell of LCL, express a range of viral genes,
including 3 LMPs 6 EBNAs, along with 2 non-coding RNAs (EBERs) (Fields et al.,

16

2007; Rickinson et al., 1984; Wang et al., 2010). The transcription of these viral genes
is regulated by several different promoters, including Cp, Wp and Qp, which appear to
be activated in different latency programs (Brooks et al., 1992).

1.9 EBV encoded RNAs

1.9.1 Synthesis and expression of EBERs

EBV encoded RNA EBER1 and EBER2 are two small RNAs that are nonpolyadenylated and noncoding. They are present abundantly in all latent stages and
expressed at a very high numbers, upto ~107copies per cell (Arrand & Rymo, 1982; Lerner
et al., 1981). Their high expression in EBV infected cells makes them an ideal target for
EBV detection through in situ hybridization (Chang et al., 1992; Khan et al., 1992).
Studies have shown that EBER1 is expressed ~106 and EBER2 is present approximately
~2.5 x 105 per cell (Moss & Steitz, 2013). Both EBERs are transcribed approximately at
equal rates but due to the longer half-life of EBER1, it is present at 10 fold higher levels
compared to EBER2 (Clarke et al., 1992). Actinomycin D treatment has shown that the
EBER2 half-life was 45 minutes while EBER1 was around 8-9 hours (Clarke et al., 1992).
In newly infected cells, the expression of EBERs was observed after 36 hours while the
higher levels were observed only after 70 hours post infections (Alfieri, Birkenbach, &
Kieff, 1991). Is this difference in the half-life of EBERs of any importance? Till now it is
not clear.

Recent studies have reported that EBERs are not seen in oral hairy leukoplakia,
oral papilloma or lymphoma of salivary gland and Sjogren’s syndrome tissues by in situ
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hybridization, despite active EBV replication. Furthermore, within the switch from latent
to lytic viral replication, the reduction in the expression of EBERs has been noted. It is
reported that the expression level of EBERs diversity is heterogeneous among the tumor
cells in the NPC individuals. These RNAs are expressed at high level in specific tumor
cells whilst low levels are expressed by adjacent cells (Gilligan, Rajadurai, Resnick, &
Raab-Traub, 1990; Knecht et al., 1990).

The transcription start site of EBERs are found on the EBV EcoRI J fragment of
B95.8 genome (position number 6628-6796 and 6958-7129 bp) and is separated by 161
bp region. EBERs have both pol III and pol II promoter elements, but they are mostly
transcribed by pol III (Rosa et al., 1981). Interestingly, downstream promoter elements
including Box B (+50) and Box A (+10) are required by pol III (Rymo, 1979) for high
EBERs expression level. It is reported that Box A mutation leads to reduction in 20% of
EBERs transcription while Box B mutation reduces 97% of EBERs transcription in
comparison to wild type (Howe & Shu, 1989). EBERs expression is further enhanced by
three upstream elements along with the RNA pol II promoter element. These upstream
elements including an ATF motif, Sp1-like and TGTA in the upstream EBER1 promoter
or TATA box in the upstream EBER2 promoter stimulates the EBERs expression upto
50-fold in vivo. These findings suggested that EBERs are also transcribed by pol II
(Ahmed et al., 2014; Yao et al., 1996). Two further enhancer elements CAGATG and
CACGTG are required for EBER1 expression, but not EBER2 (Niller et al., 2003).
Although the similarities of regulatory arrangement between EBER1 and EBER2 are at
high level, any mutation or deletion in them leads to reduction of the EBERs expression
(Howe & Shu, 1989).
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The level of EBERs expression is influenced by a potent promoter and cellular and
viral transcription factors. It has been reported that viral protein, EBNA1, plays a role as
transcription factor for polymerase III C (TFIIIC) and activation of ATF2 (transcription
factor 2) (Felton-Edkins et al., 2006; Owen et al., 2010). In EBV infected cells, ATF2 is
phosphorylated leading to interaction with EBERs promoter (Felton-Edkins et al., 2006).
Furthermore, EBNA1 and 2 expression induces the binding of proto-oncogene c-MYC
with two E box elements that promotes EBER1 expression (Niller et al., 2003; Spender,
Cornish, Sullivan, & Farrell, 2002). Poly-thymidine region in the EBERs sequence acts
as a termination signal for EBERs (Bredow, Sürig, Müller, Kleinert, & Benecke, 1990;
Kickhoefer, Emre, Stephen, Poderycki, & Rome, 2003).

1.9.2 Structure of EBERs

EBER1 is 167, whereas EBER2 is 172 nucleotides in length and both have 54%
homology in their sequences (Figure 1.3) (Lerner et al., 1981). EBERs are present close
to the origin of replication (OriP) and transcribed from left to right by RNA polymerase
III. Despite the relatively low sequence homology, they are similar in their secondary
structures containing several short stem loops. The EBERs primary sequence is observed
to be highly conserved among EBV strains, despite the few changes that had been
observed. Similarly, polymorphism of EBERs has been shown in gastric cancer and NPC
cases, in which EBER1 was observed to be highly conserved, except for three sequence
variations in the intergenic region and six changes in the sequence of EBER2 were
observed (Wang et al., 2010).
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The conservation within EBERs sequences suggests that they are important in the
EBV life cycle. Thus, their secondary structures and the conservation between the
structures are probably critical for the EBER1 and EBER2 function. For example, in
EBER1, the guanine residues replacement with inosine disables the binding of EBER1
secondary structure with PKR complex (Katze et al., 1991). Studies have shown that the
secondary structure of adenovirus associated RNAs (VA1 and VA2) which are also nonpolyadenylated are similar to that of EBERs (Rosa et al., 1981). VAs play an essential
role in the replication and translation of the adenovirus. VA1 deletion was reported to
have a significant effect on replication of the virus (Thimmappaya, Weinberger,
Schneider, & Shenk, 1982). It was shown that EBERs were able to substitute the function
of VA1 in VA1-deleted cell lines and rescue the adenovirus replication (Katze et al.,
1991). The similarities between Herpesvirus papio (HVP) RNA type 1 and 2 and EBERs
were also reported. HVP RNA type 1 is 83% sequence identical to EBER1 and HVP2
shares 65% similarity with EBER2, in addition to their secondary structures and regions
of promoter (50-60%) (Iwakiri & Takada, 2010).
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Figure 1.3: EBERs secondary structure, EBER1 is 167 nucleotides, while
EBER2 is 172 nucleotides long. EBER1 and EBER2 have 54% sequence
homology. Image adapted from: (Iwakiri, 2014)
1.9.3 EBER localization

EBERs are mainly observed in the nucleus of EBV infected with cells. This can
be seen through in situ hybridization (ISH) staining of EBERs (Chang et al., 1992; Howe
& Steitz, 1986; Khan et al., 1992). Previous studies indicated that using confocal laser
scanning microscopy at high resolution ISH on Raji cell, EBERs may be associated with
perinuclear region of the cells, corresponding to the locations of Golgi apparatus and
endoplasmic reticulum (Fok et al., 2006; Schwemmle et al., 1992). Moreover, recent
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studies have shown that EBERs can also be secreted in exosomes along with lupus antigen
protein (La) as a complex (Ahmed et al., 2014; Ahmed et al., 2018; Iwakiri, 2014).

1.9.4 EBERs interaction with cellular proteins

La protein

The La protein is one of the most abundantly expressed proteins in human cells
(2x107 per cell). Anti-La antibodies precipitated EBERs from nuclear RNP
(ribonucleoprotein)

complex in samples from systemic lupus erythematosus (SLE)

patients (Lerner et al., 1981). Uridylate residues short sequence which presents the
common motif in EBERs appears to be the interaction site with La antigen. In this
complex, the interaction of La antigen with gene products of RNA polymerase III is lost
at the 3'-end upon RNA maturation. For the most RNAs, this binding is not permanent,
but is stable in the case of EBERs (Howe & Shu, 1988). Furthermore, the importance of
this interaction is unknown. Although La is mainly localized in the nucleus, it is also
observed in the cytoplasm under certain conditions. A previous study suggested that
EBERs-La interaction is important in terms of helping EBERs to transport out from EBV
infected cells to the neighboring cells (Ahmed, Attoub, Khan, & Philip, 2015; Iwakiri,
2014).

PKR

PKR, which is also known as human double-stranded RNA-regulated protein kinase,
is a 551 MW enzyme. Its N-terminus contains two conserved 70-residue dsRNA-binding
motifs (dsRBM I and II). However, its C terminus has a serine/threonine kinase catalytic
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domain. PKR is activated and auto phosphorylated by dsRNA, leading to the
phosphorylation of the initiation factor eIF-2α thereby blocking initiation of protein
synthesis and inducing apoptosis. EBER1 has been shown to bind to PKR at stem loop
IV, and inhibits the phosphorylation of PKR (Lerner et al., 1981; Yoneyama & Fujita,
2007). This in turn blocks eIF-2α phosphorylation and inhibits apoptosis induced by IFNα (Fok et al., 2006; Sharp et al., 1993).

Similar to EBER1, PKR is bound by VA RNAs of adenovirus, an IFN inducible
threonine/serine kinase that acts as the antiviral key mediator (Vuyisich, 2002).
Demonstrating that VAs/ EBERs binding to the PKR de-phosphorylation form is as strong
as other dsRNA activators, but VAs/ EBER1 prevents trans-autophosphorylation of PKR
by blocking the PKR dimerization.

L22

L22, a ribosomal protein, is part of the 60s eukaryotic ribosomal subunit and
interacts with viral RNA and cellular proteins through histone H1 and human telomerase
RNA (TERC) (Le, Sternglanz, & Greider, 2000; Ni, Liu, Hess, Rietdorf, & Sun, 2006).
However, the importance of this interaction is not clear. Studies have shown that EBER1
and EBER2 bind to ribosomal protein L22 in EBV infected cells (Toczyski & Steitz,
1991). EBER1 binds with the L22 ribosomal protein by stem loop 1, 3 and 4 (Fok et al.,
2006; Toczyski et al., 1994). Interaction between L22 and small RNAs are also noted in
hepatitis C and herpes simplex virus (Leopardi et al., 1997; Wood et al., 2001).
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Normally, L22 is found in cytoplasm and nucleoli of B lymphocytes. Interestingly,
upon EBV infection, it is transferred to nucleoplasm by EBERs (Toczyski et al., 1994). In
tumor cell types, re-localization of L22 from nucleoli to nucleoplasm results in decrease
of L22 from ribosomes (Jennifer L. Houmani & Ruf, 2009; Toczyski et al., 1994). Studies
suggested that the distribution of L22 may vary depending on the cell type. In the case of
293T cells, it is localized in nucleus whereas in the EBV-immortalized lymphoblastoid
cells, it is in the cytoplasm (Gregorovic et al., 2011).

Toll-like receptor 3

Toll-like receptor 3 (TLR3) has a role in the innate immune response to evade
pathogens by dsRNAs recognitions (Medzhitov et al., 1997; Rock et al., 1998). TLR3
receptor is expressed by variety of epithelial cells and conventional dendritic cells (Rock
et al., 1998). Recently, it was demonstrated that EBERs-La complexes are released from
infected cells through exosomes (Ahmed et al., 2014; Iwakiri et al., 2009) which are taken
up by endocytosis. Therefore, intracellular TLR3 is activated leading to transcript IFN- α
by the master key transcription factor NF-κB and pro-inflammatory cytokine production
(Karikó, Ni, Capodici, Lamphier, & Weissman, 2004; Lee, Dunzendorfer, Soldau, &
Tobias, 2006).

AU-rich element binding factor1
AU-rich element binding factor1 (AUF1) is able to bind to 3′-untranslated
regions of precursor RNA by AU-rich elements (Lu et al., 2006; Sadri & Schneider, 2009).
The role of the AUF1 protein in the nucleus associates with pre-mRNA to promote the
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short-lived mRNA decay. Further to its binding with mRNA, involving cell cycle
regulators, cytokines and proto oncogenes induce their decompositions (Loflin, Chen, &
Shyu, 1999).

At the chromosome level, studies suggested that the AUF1 plays a role in the
stabilization of particular transcripts (Lal et al., 2004). Also it is involved in telomerase
maintenance, regulating telomerase expression and senescence suppression (Pant, Hilton,
& Burczynski, 2012). A recent report showed that AUF1 is a novel partner of EBER1.
Interestingly, electrophoretic shift assay showed that EBER1 competes with other mRNA
for the AUF1 binding, and thus results in the inhibition of the short lived mRNA-AUF1
interactions (Lee, Pimienta, & Steitz, 2012). The EBER1-AUF1 interaction could lead to
the increase in the specific ARE levels containing mRNAs resulting in over expression of
AUF1and therefore could contribute to EBV mediated oncogenesis (Gouble et al., 2002).
AUF1 has also been shown to have the ability to control the anti-viral activity by inhibiting
viral translation as is observed in human rhinovirus and enterovirus infected cells
(Cathcart, Rozovics, & Semler, 2013). Binding of AUF1 with EBER1 could inhibit any
potential antiviral effects during EBV infection. Also this interaction can lead to shuttling
the AUF1 from nucleus to cytoplasm, as it is found in human polio virus and rhinovirusinfected cells (Rozovics et al., 2012).
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1.9.5 Effect of EBERs on EBV infected cells

Resistance to Apoptosis by EBERs

The ability of EBERs to interact and inactivate a number of cellular factors that
plays a role in the stimulation of apoptosis and innate viral sensing, suggests that EBERs
may be involved in inhibiting apoptosis. Studies have shown that EBERs provide
resistance in

BL cell line (Akata, EBV-positive) to the glucocorticoid, hypoxic,

cycloheximide stress and UV light apoptotic inducers (Komano et al., 1999). Similarly,
in EBERs-transfected NPC cell line, which was exposed to poly(I:C), resulted in lower
cell death compared to controls (Wong et al., 2005). Some studies reported that EBERs
induce resistance to cell death in the serum depleted conditions in BJAB transfected cell
lines. EBERs have also been shown to provide resistance to extrinsic apoptosis mediators
such as FAS ligand in BJAB and epithelial cell lines (Nanbo et al., 2005; Yamamoto et
al., 2000).

At the molecular level, the activation of PKR leads to IFN-α induction resulting
in induction of antiviral cascade (Fuertes, Woo, Burnett, Fu, & Gajewski, 2013).
However, EBERs cellular interaction with dsRNA-PKR, was shown to prevent the autophosphorylation and DAI activation (Mathews & Shenk, 1991). This DAI when activated,
phosphorylates polypeptide chain initiation factor elF-2α subunit (Clarke et al., 1992;
Levin et al., 1980; Siekierka et al., 1985). This interaction results in inhibition of protein
synthesis and subsequently induce apoptosis (Ahmed & Khan, 2014; Yoneyama et al.,
1998). EBERs provide resistance to PKR induced apoptosis in Burkitt’s lymphoma cells
(Nanbo, Inoue, Adachi-Takasawa, & Takada, 2002).
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Role of EBERs in cell proliferation

In vitro studies have reported that EBERs enhance the growth rate in the epithelial
cells derived from nasopharyngeal carcinoma and gastric cancer (Wong et al., 2005;
Yoshizaki et al., 2007). Similarly, in vivo studies supported the significant role of EBERs
in tumorigenesis by inducing lymphoma and hyperplasia in transgenic mice expressing
EBERs (Repellin, Tsimbouri, Philbey, & Wilson, 2010). The increased growth rate in the
EBERs-positive cells appears to be by inducing autocrine growth (IGF1) factor which has
been shown to be expressed at a higher amount in biopsies of EBV-positive NPC samples
compared to EBV-negative NPC samples. This suggests that EBERs are associated with
developing epithelial cancerous cells by inducing autocrine growth (Iwakiri, Sheen, Chen,
Huang, & Takada, 2005). Using various EBV infected cell lines, the role of EBERs in
EBV mediated oncogenesis has been reported to be inducing various cytokines such as
IL-9 and IL-10 (Kitagawa et al., 2000). IL-10 was observed to act as an autocrine growth
factor for B cell activation and proliferation (Mege et al., 2006). Interestingly, in B cells,
EBERs-positive EBV was 100 fold higher in B cell transformation than EBERs-deleted
EBV, proposing that EBERs may contribute to efficient growth of B lymphocytes
transformation (Yajima, Kanda, & Takada, 2005). However, in previous study showed
that no difference was observed in B cell transformation between wild-type and EBER
deficient EBV (Gregorovic et al., 2015). The different observations because of different
EBV strains were used in the two studies. Some studies showed that the tumorigenicity
and cell proliferation in B lymphocytes is induced by EBER1 (Houmani, Davis, & Ruf,
2009). In the T cells, IL-9 an autocrine growth factor has been reported to induce
proliferation. Interestingly, 3 out of 4 biopsies of the EBV positive T/NK nasal
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lymphomas have shown overexpression of IL-9, suggesting EBERs play a role in inducing
IL-9 expression in these lymphomas (Yang et al., 2004). Still there is controversy in
studies regarding which of the two EBERs are of importance for tumorgenicity and cell
proliferation?

1.10 Hypothesis and aims of the study

A number of studies have shown that EBER1 can induce cell proliferation in EBV
infected cells or EBER1 transfected cells (Clemens, 2006). Furthermore, EBER1 probably
achieves this functional feature by interacting with the cellular proteins. The presence of
EBERs could enhance the IL-10 production for cell proliferation (Yang, Aozasa, Oshimi,
& Takada, 2004). Based on these observations, it is possible that EBER1 may promote
potential mechanisms involved in the IL-10 pathway to induce proliferation in the
immortalized cells. So, the specific aims for this study were:

1. To study the role of EBER1 in cell proliferation.
2. To investigate the potential molecular mechanism involved in EBER1 induced cell
proliferation.
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Chapter 2: Material and Methods
2.1 Cell lines and materials

2.1.1 Culture media and reagents

Media *1

Media*2

Working Concentrations

DMEM (Dulbecco’s

RPMI(Roswell Park

500 ml

Modified Eagle’s

Memorial Institute) 1640

Medium) containing L-

(Gibco)

glutamine (Gibco)
Fetal Bovine serum (FBS)

Fetal Bovine serum (FBS)

50 ml (10%)

Antibiotic antimycotic

Antibiotic antimycotic

5 ml (10 µl/ml)

(Santacruz)

(Santacruz)

Gentamycin

Gentamycin

0.5 ml (50 µg/ml)

L-glutamine (Gibco)

5 ml

Hygromycin B

150 µg/ml

Hygromycin B
Additional Reagents

Phosphate buffered saline (PBS) (Gibco)
Trypsin-EDTA solution (Gibco)
Tissue culture flask T75 (Nunc)
Tissue culture flask T25 (Nnmc)
Culture Conditions
All cell lines were incubated in the incubator humidified at 37oC and
supplemented with 5% CO2.
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2.1.2 Type of cell lines

The cell lines used in this study are listed in Table 2.1 along with their appropriate
culture conditions.
Table 2.1: The table shows the list of cell lines used in this study. The characteristic for
each cell line with the appropriate culture conditions are given.
Cell line

Features

293T-Hebo

Human embryonic kidney
epithelial cell (stably
transfected with pHEBo
plasmid).
Adherent cell line.

293T-ER1

BJAB- Hebo

BJAB-ER1

Jurkat-Hebo

Jurkat -ER1

Culture
Requirements
Media *1

Reference

Human embryonic kidney
epithelial cell (stably
transfected with
pHEBoEBER1 plasmid).
Adherent cell line
Burkitt lymphomaderived B-cell (stably
transfected with pHEBo
plasmid)
Suspension cell line
Burkitt lymphomaderived B-cell (stably
transfected with pHEBo
EBER1 plasmid).
Suspension cell line

Media *1

(Ahmed et al.,
2014)

Media *2

Khan Lab

Media *2

Khan Lab

Human T cell (stably
transfected with pHEBo
plasmid)
Suspension cell line
Human T cell (stably
transfected with pHEBo
EBER1 plasmid)
Suspension cell line

Media *2

Khan Lab

Media *2

Khan Lab

(Ahmed et al.,
2014)
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2.1.3 Cell thawing

The growth media (20% FBS) was warmed up at 37°C water bath. The frozen cell
vials were taken out from liquid nitrogen tank, kept directly on ice and thawed quickly by
keeping at 37°C water bath (until the sides were seen thawed but the insides still in a
frozen state). After that, the cells were re-suspended in 3 ml of warm media using 5 ml
pipette and transferred to a 15 ml conical tube. The cells were spun down at 1000 rpm for
5 minutes and the media was aspirated. The cell pellet was then re-suspended in 5 ml of
20% FBS media and moved into a labeled T25 flask and kept in the CO2 incubator.

2.1.4 Cell freezing
Cells at passage 3 or 4 were split and grown to 1 x 106 cells/ml in incubator for
freezing in appropriate freezing media. For adherent cell lines, 1XPBS was used for
washing the cells gently. Cells were then trypsinized with 1xtrypsin for about 2 minutes
at 37°C, centrifuged at 1000 rpm for 5 minutes and counted using trypan blue (Sigma Cat#
T8154) exclusion method. Non-adherent cell lines were collected and centrifuged in the
same way, except that the initial trypsinization was not required. Supernatant was
discarded and the cells were resuspened in 0.5 ml/vial of FBS. Freezing media (for both
adherent and non-adherent cell lines) consisted of 10% dimethyl sulfoxide (DMSO) in
RPMI or DMEM. Cells were gently mixed in freezing media 1:1 volume and aliquoted
into 1 ml cryovials which were put in Mr. Frosty (Nalgene, Cat#5100) that contained
isopropanol for slow freezing at -80°C. The following day, vials were transferred to liquid
nitrogen for long-term storage.
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2.2 Fixation and hybridization of cells
For embedding, 10 x 106 cells/ ml were collected and spun at 1500 rpm for 5
minutes. Cell pellet was washed once using cold 1XPBS and centrifuged again as
mentioned above. After PBS was discarded, the pellet was re-suspended in 3 ml of 4%
paraformaldehyde and kept for 2 hours at room temperature for fixation. After 2 hours,
cells were spun down at 1200 rpm for 10 minutes and washed once with 1XPBS to remove
the paraformaldehyde. The cell pellet was resuspended in 10 ml of 1XPBS and moved to
a fresh 15 ml conical tube. As mentioned previously, resuspended cells were centrifuged
and PBS was decanted gently and ~100 µl of left-over PBS was used to resuspend the cell
clumps by tapping the bottom of the tube gently. 1 ml of 2% agarose in 1XPBS, cooled to
50°C, was added to the cells and pulse centrifuged at 1000 rpm so that the agarose would
settle and solidify. Agarose cone was taken out of the 15 ml tube by gently tapping the
bottom of the conical tube. The cone was divided into two halves by using sharp scalpel
and transferred to labeled embedding cassettes. The cones were then processed to make
paraffin blocks.

2.2.1 Embedding and sectioning of cells

The cells were dehydrated by incubating the cassettes in ascending concentration
of ethanol, 30%, 50%, 70% and 90% for 30 minutes each. Further incubation was done in
absolute ethanol (100%) for 60 minutes to make sure the remaining water was removed.
To clear out agarose cones, they were incubated in ethanol-xylene mixture (1:1) for half
an hour and in absolute xylene for 30 minutes.
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After that, molten paraffin wax (Histoplast PE, Thermo Scientific, Cat# 8330) was
used to impregnate the cones with two wax changes at 55°C for 30 minutes each. The flat
surfaces of agarose cones were put in the mold's bottom, the cassettes were put on top and
wax was added. The extra paraffin wax was removed from the sides after it cooled down
to make sure it can fit properly in the microtome block holder.

Microtomy

For better sectioning, the paraffin blocks were incubated in the fridge overnight to
cool down. The blocks were aligned and 10-15 µm thick sections were trimmed down to
ensure that there was no excessive paraffin. Cells were sectioned at 5 µm thickness and
floated on water bath at 40°C. Sections were collected using labelled slides coated with
3-aminpropyltriethoxysilane (APTES, Sigma, Cat# A3648) and dried on a hot plate.

2.2.2 EBER in situ hybridization

To detect EBERs in the transfected cell lines and EBV infected cell lines (B95.8)
as positive control, EBERs in situ hybridization (EBERs-ISH) was done as previously
described (Khan et al., 1992). For detection of EBER1 (30-mer oligonucleotides) sense
and antisense probes were designed specifically. Each probe was labeled using
digoxigenin (DIG) Oligonucleotide Tailing Kit which is commercially available and used
according to manufacturer’s instructions (Roche, Cat#03353583910). EBER1 was used at
0.2 µg/ml final concentration for hybridization follows:

1. The slides were pre-warmed at 42°C for one hour, so that the paraffin wax would
melt. Then, were washed twice in Xylene for 10 minutes each to remove paraffin.
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Then, dehydrated in graded concentration of ethanol (70%, 90%, 100%) each for
5 minutes to remove Xylene from the sections.
2. The activity of endogenous peroxidase was inhibited by incubating the sections in
0.5% H2O2 (Panreac, Cat# 121076) in methanol (Panreac, Cat# 131091) for 20
minutes so that non-specific staining could be avoided. After that the slides were
dehydrated by incubating them for 1 minute in graded concentration of ethanol
(70%, 90% and 100%) and air dried.
3. The slides were pre-warmed in a humid chamber at 37°C for 10 minutes. To each
section 200 µl of proteinase k (final concentration 100µg/ml) diluted in TE (Tris
EDTA) were added and incubated for 10 minutes. The slides were washed in
distilled water for 3 times and rinsed in graded ethanol (70%, 90%, and 100%).
Slides were then air dried and sections were marked with a diamond pen before
proceeding for hybridization.

Hybridization
Dig labeled EBER1 probe were diluted in hybridization buffer (see Appendix I),
the probe's final concentration was 0.2 µg/ml (1:50 of 10 µg/ml working stock) in the
hybridization mix.
1. To each section, 16 µl of the hybridization mix containing the probe was added
and 22x32 mm coverslip was overlaid on the section (Sigma, Cat# 06522) to
prevent evaporation.
2. The slides were hybridized in a humidified chamber that contains filter papers
soaked in 2XSSC. The slides were heated in a domestic microwave (National,

34

model#5V52220389) at minimum power for 7 minutes and incubated at 42°C
overnight in heated oven.
3. Next day, the slides were transferred to a coupling jar containing 2XSSC and
the coverslips were removed by tapping gently. The slides were washed twice
in 2XSSC for 5 minutes on an orbital shaker.
4. Stringent washes were performed to remove any excess probe, thus preventing
non-specific binding. It was done by incubation of the slides in a coupling jar
containing pre-warmed 0.1XSSC at 50°C in a shaking water bath. The
incubation lasted for 10 minutes and the slides were washed twice.
5. The slides were washed twice for 10 minutes in 2XSSC followed by 1XPBS
for 10 minutes.
Signal detection
6. Mouse anti-DIG monoclonal antibody, which is the primary antibody (clone
D1-22, Sigma, Cat# D8156), was diluted to 1:2500 ratio in 1XPBS containing
horse serum at 1:100 ratio. To each section, 150-200 µl was added very quickly
without drying the sections. Incubation was done overnight in a humidified
chamber at 4°C.
7. Next day, the sections were transferred to a coupling jar which contained
1XPBS and washed for three times, 10 minutes each by putting them on an
orbital shaker.
8.

Biotinylated anti-mouse secondary antibody (Thermo scientific, Cat # 35052)
was diluted to a concentration of 1:200 in 1XPBS that contained horse serum at
1:100. As previously mentioned, the slides were incubated for an hour in a
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humidified chamber at room temperature with 150-200 µl of secondary
antibody for each section, followed by 3 washes in 1XPBS.
9. To prepare the ABC reagent (avidin biotinylated peroxidase complex, Thermo
scientific, Cat# 32052), each reagent was diluted at 1:50 concentration in 1X
PBS. For stabilization purposes, the reagent was prepared fresh 45 minutes
before use. Around 150-200 µl of the reagent was added on each section and
slides were kept for 30 minutes in humidified chamber at room temperature.
Then the slides were washed 3 times in 1XPBS.
10. Signal detection was done using DAB substrate (3, 3' diaminobenzidine, Sigma,
Cat#D5637) which was fixed by adding 0.02% hydrogen peroxide and 1 ml of
25 mg DAB into 100 ml of 1XPBS. Slides were incubated in DAB solution for
30 minutes. Then the slides were washed three times in water.
11. The sections were counter stained with Harris hematoxylin (Thermo Scientific,
Cat# 6765015) for about 2 minutes. Slides were instantly washed with tap water
and in acid alcohol (1% HCl in 70% ethanol) for 1 minute to eliminate any nonspecific staining and to better define the nuclei. Then, the slides were put under
running tap water for 10 minutes to blue the sections.
12. In absolute ethanol, slides were dehydrated for 1 minute each, air dried and
washed in Xylene. Using Xylene based DPX mounting medium, sections were
mounted and coversliped. A light microscope was used to observe the slides
closely.
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2.3. Proliferation assays

2.3.1 Counting experiment

To compare cell proliferation of cells transfected with EBER1 and Hebo plasmids,
experiments were carried out as follows. For adherent cells, 2.5×104 cells/well were plated
onto a NunclonTM DELTA Surface 24 well plate. The cells were grown in complete
growth media at 37°C incubated with 5% CO2 for six days. For the first three days, the
cells were trypsinized each day with 50 µl of 1xtrypsin in 500 µl of complete media and
counted. However, the last three days the cells were trypsinized with 100 µl and counted
using trypan blue assay.
For non-adherent cells, 5 × 104 cells/well were plated in 24 well plates and cells
were counted each day using the trypan blue exclusion assay. Each time point (1-6 days)
was done in quadruplicates and three independent experiments were done. The mean
growth curve was plotted along with the standard errors of the means (SEMs).

2.3.2 Cell viability assay

To differentiate the cell viability between the cells which were expressing EBER1
compared to the control, cells were grown in appropriate media and counted by trypan
blue exclusion assay. Around 2.5 x 103 of 293T cells and 8 x 103 of BJAB and Jurkat cells
per well were plated in 100 μl of complete media in 96 well white flat bottom plates (F96
MicroWellTM White Polystyrene plate, Cat# 136101, Thermo, USA). Negative control
wells had equal volume of media without cells, and were grown in incubator supplemented
with 5% CO2 at 37°C.
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The viability of the cells was measured by the CellTiter-Glo® Luminescent Cell
Viability Assay Kit (Cat#G7570, Promega, USA) by following the manufacturer’s
instructions. At different time points (24, 48, 72 and 96 hours) 50 μl of media was
cautiously aspirated from the wells and replaced with 50 μl of the viability reagent and
plate was covered by aluminum foil to avoid light sensitivity. The plate was incubated at
room temperature for 10 minutes on a rocking platform. Readings were recorded using
multilabel plate reader (Victor X3, PerkinElmer, USA) with luminescence settings. The
viable cells were calculated using the following formula:
𝑂𝐷 𝑜𝑓 𝑡𝑒𝑠𝑡 𝑐𝑒𝑙𝑙𝑠 (𝐸𝑅1)

Viability = 𝑂𝐷 𝑜𝑓 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 𝑐𝑒𝑙𝑙𝑠 (𝑝𝐻𝑒𝑏𝑜)
2.3.3 Serum deprivation

To investigate the proliferation activity in EBER 1 expressing cells compared to
the control under serum deprivation condition. For 293T cells, 2.5×104 cells per well,
transfected with EBER1 or Hebo plasmids were plated in a NunclonTM DELTA Surface
24 well plate. After 24 hours, the complete media was exchanged with serum depleted
media. For next 6 days, the cells were trypsinzed each day after 24 hours and collected in
500 µl of media and counted using trypan blue. However, for non-adherent cells, 5 × 104
of EBER1 expressing cells and control were plated (1 ml/well) with serum free media in
24 well plates. The cells were collected in 1ml media and counted with trypan blue assay
for every 24 hours. Each time point was counted in quadruplicates and three independent
experiments were done.
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2.3.4 Soft agar colony formation assay

To determine the effect of EBER1 on anchored independent growth, and its ability
to form colonies in soft agar, The soft agar assay was performed in 6 well plates (Arafat
et al., 2013). Briefly, 2.4% of agar (Bacto agar, Sigma) was dissolved in ddH2O and was
autoclaved. Agar was cooled down to 40-50°C and 1ml was added to each well. Gently,
the plate was swirled so the agar would cover the well surface. The plate was kept at 4°C
for 2 hours to solidify the agar. The plates were then transferred to 37°C incubator. The
293T, BJAB and Jurkat cells were counted using trypan blue exclusion assay. A total of
0.04 x 106 cells/ well were resuspended in 2.5 ml of DMEM or RPMI media (according
to the cell type) with 0.4 ml of warm agar. The cells were then gently layered onto the soft
agar base and kept at 37°C incubator. PBS was used as negative control (without cells).
Every two days, the media was gently aspirated and fresh 2 ml media was added in each
well. The size of the colonies was monitored throughout for a period of 5-14 days using a
light microscope.

2.4 Gene expression studies

2.4.1 RNA isolation from cells
For RNA isolation from cells, 2x106 cells were collected in a 15 ml conical tube,
centrifuged at 1500 rpm at 4°C for 10 minutes and media was aspirated cautiously. Ice
cold 1XPBS was used for washing the cell pellet, and cells were spun down under the
same conditions as described above. RNA was extracted from cells using 1ml of TRIzol
(Invitrogen, USA). The cells were incubated at room temperature for 10 minutes and the
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transferred to a 1.5 ml eppendorf tube and 200 µl of chloroform was added. The eppendorf
tubes were shaken vigorously and incubated for 2-3 minutes at room temperature. Samples
were centrifuged at 13,000 rpm for 15 minutes at 4°C. After that, 3 layers were noticed
with an aqueous phase that contained RNA. The upper layer was transferred to a fresh
eppendorf tube and 600 μl of isopropanol was gently mixed with it. RNA was precipitated
for 10 minutes at room temperature and was pelleted after centrifugation at 13,000 rpm
for 10 minutes at 4°C. The white RNA pellet observed was rinsed with 1 ml of 75%
ethanol and was spun at 8,000 rpm for 10 minutes to eliminate any possible contaminating
proteins. The pellet was air dried for 15 to 30 minutes to remove any residual ethanol. The
pellet was re-suspended in RNase-free H2O. To ensure that the RNA pellet was dissolved
properly, it was incubated for 10 minutes at 55°C. Nanodrop (Nanodrop 2000c,
Thermoscientific) was used to quantify the RNA concentration. The samples were frozen
at -80°C for downstream applications.

2.4.2 cDNA preparation

Of the isolated RNA, 4 µg was used for the cDNA synthesis. Dnase1 enzyme was
used to eliminate any DNA contamination from the isolated samples (Promega). Dnase
treatment was done as follows:

Reconstituted RNA (4 µg)

30 µl

10X DNase buffer (1X)

3 µl

RNasin (1 U/µg RNA)

1 µl
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DNase1 (1 U/µg RNA)

2 µl

The RNA samples were incubated for 60 minutes at 37°C on a thermomixer,
followed by addition of 3 µl of stop buffer (20 mM EGTA, Promega, Cat# M199A). The
samples were incubated for 10 minutes at 65°C to stop the enzymatic activity. One micro
liter of DNase treated RNA was tested by PCR to make sure the RNA was without any
contaminating DNA. GAPDH primers were used for this process. After confirming the
absence of amplification, DNased-RNA was converted into cDNA through the reverse
transcription reaction using a commercially available Promega kit, following the
manufacturer’s instructions (Reverse Transcription System, A3500 Promega).

Briefly, the DNase treated RNA was incubated in thermomixer for 10 minutes at
70°C and then immediately kept on ice. The reaction mixture was prepared as follow:

25 mM MgCl2 (5 mM)

12 µl

10X Reverse Transcriptase Buffer (1X)

6 µl

10 mM dNTP’s (1 mM)

6 µl

Random Hexamer (0.5 µg/µl RNA)

2 µl

AMV Reverse Transcriptase (15 U/µg RNA)

3 µl

DNased-RNA

~30 µl

The samples were incubated for 10 minutes at room temperature, then for an hour
at 42°C. Then to stop the reaction the samples were incubated for 5 minutes at 95°C. They
were put on ice instantly, aliquoted and stored at -80°C.
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2.4.3 Reverse transcriptase polymerase chain reaction (RT-PCR)

The quality of cDNA was examined by RT-PCR using housekeeping gene
GAPDH and/or EBER1 specific primers. The final volume for each PCR reaction was set
at 30 μl. The list of primer sets used are mentioned in table 2.2. The reaction mixture was
prepared as follows:

10 XPCR mix (1X)

3 µl

25 mM MgCl2 (2 mM)

0.5 µl

dNTPs (0.5 mM)

0.15 µl

Primer Forward (10 pM)

1 µl

Primer Reverse (10 pM)

1 µl

Taq Polymerase (1 U)

0.2 µl

Nuclease free H2O

22.15 µl

Template

2 µl
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The amplification profile was set as follow:

30 cycles

94°◦C

94°C

5 min

1 min

72°C
55°◦C

1 min

30 sec

72°C
7 min

4°C

∞

Each PCR batch included B95.8 cDNA as positive control and appropriate negative
control. Applied Biosystems thermal cycler PCR System 2700 was used to set all PCR
reactions. The amplified products were run by electrophoresis at 120 volts on 2.5%
agarose gel and stained with ethidium bromide and visualized by gel documentation
system.

2.4.4 Quantitative Real Time PCR (qRT-PCR)

Real time PCR was performed to determine the expression of proliferation markers
(Ki67, PCNA and MCM2) at the RNA level in the stably transfected cell lines. Cellular
RNA was isolated using TRIzol reagent as described in section 2.3.1. For this study, 4 μg
of cellular RNA was converted into cDNA as explained above in section 2.3.2. Each
experiment was repeated three times. The qPCR reaction was prepared as follows:

2X Sybr PCR mix (1X)

10 µl

Primer Forward (10 pM)

1 µl
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Primer Reverse (10 pM)

1 µl

Nuclease free H2O

6 µl

Template

2 µl

The primer sequences of Ki67, PCNA and MCM2, together with the primers for
the house-keeping gene β-actin are listed in table 2.2. Using MicroAmp® Optical 96-well
plates (Applied Biosystems) in dark laminar flow hood, 20 µl of reaction was set as final
volume and each sample was done in duplicates. Using MicroAmpTM optical adhesive
film, the plate was covered, spun down at 2000 rpm for 1 minute and placed in
QuantStudioTM 7 Flex Real-Time PCR System (Applied Biosystems, Germany). The
annealing temperature was set up at 55°C. The following formula was used to calculate
the relative quantification (RQ).

TE = Tested Experimental.
TC= Tested Control
HE= Housekeeping Gene Experimental
HC= Housekeeping Gene Control
ΔCt Experimental (ΔCtE)= TE - HE
ΔCt Control (ΔCtC)= TC-HC
ΔΔCt = ΔCtE-ΔCTC
RQ= 2^-ΔΔCt
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Table 2.2: List of primers, 10pM as working concentrations was used for amplification
of viral and cellular genes.
Sequences (5’ 3’)

Primer Name

Orientation

EBER1

Forward

CCC AGA TCT AGG ACC TAC GCT GCC C

EBER1

Reverse

CCC AAG CTT AAA ACA TGC GGA CCA CCA
GC

Ki67

Forward

TCC TTT GGT GGG CAC CTA AGA CCT G

Ki67

Reverse

TGA TGG TTG AGG TCG TTC CTT GAT G

PCNA

Forward

CTT TTG CAC TGA GGT ACC TG

PCNA

Reverse

GTG TCC CAT ATC CGC AAT TTT

MCM2

Forward

TGC CAG CAT TGC TCC TTC C

MCM2

Reverse

AAA CTG CGA CTT CGC TGT GC

GAPDH

Forward

GCC TCC TGC ACC ACC AAC TG

GAPDH

Reverse

CGA CGC CTG CTT CAC CAC CTT CT

β-actin

Forward

TGT TAC CAA CTG GGA CGA CA

β-actin

Reverse

CTG GGT CAT CTT TTC ACG GT

2.4.5 Western blotting

To verify and identify the cellular proteins of proliferation markers between
EBER1 expressing cells and control, western blot was employed. Cells were collected,
washed with 1XPBS and saved in -8◦°C. The cells were lysed in radioimmunoprecipitation
assay (RIPA) buffer (see Appendix I). Every 1 ml of RIPA buffer had 50 μl of β-
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mercaptoethanol (Sigma), 5 μl of proteinase inhibitor and 10 μl of phenylmethylsulfonyl
fluoride (100 mM PMSF) (Sigma). The cells were kept on ice and 200 μl of RIPA buffer
/1×106 cells were added and incubated on ice for 10 minutes. 5 μl of each sample was
taken to quantify by Bradford assay (Marion, 1976) using Bio-Rad Protein Assay Dye
Reagent Concentrate (Bio-Rad Laboratories, Hercules, USA). In each assay, about 5-15
μg of the isolated protein was subsequently used. Adequate volumes of every protein was
mixed with 6x loading buffer (see Appendix) and boiled at 100°C for 5 minutes for protein
denaturation. SDS polyacrylamide gels (10%) of 1.5 mm thickness were prepared (see
Appendix I). After the samples were loaded, and electrophoresis was done by running in
1X Running Buffer made from 10X stock (see Appendix I) at 78 V for 2.5 hours. Wet
tank blotting system (Biorad) was used to electrotransfer the resolved proteins from the
gel to the PVDF membrane. They were transferred in 1X transfer buffer made from 10X
transfer buffer (see Appendix) and transferred overnight in a cold room at 30 V at 4°C.

Next day, after the transfer, the blot was washed in 1XPBST. To avoid nonspecific binding of antibodies, the blots were blocked in 5% Bovine Serum Albumin
(BSA) in 1XPBST for 2 hours on a rocker at room temperature. After blocking, the blots
were transferred to hybridization bags and incubated with primary antibody diluted in 1%
BSA overnight at 4°C. Next day, to remove the unbound antibody, the blots were washed
three times in 1X PBST for 10 minutes and incubated in 20 ml of horseradish peroxidase
(HRP) conjugated to anti-mouse or anti-rabbit secondary antibody (1:20,000 in 1% BSA)
for 1 hour at room temperature. After the incubation, the blots were washed for three times
with 1XPBST. To recognize the immune signals, ECL plus western blotting substrate was
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used (Thermo Scientific) as recommended by the manufacturer. Typhoon FLA 9500
machine was used to visualize and capture the chemiluminescent signal.

Table 2.3: Details of antibody used for western bloting:
Antibody

Clone

Cat. Number

Dilution

Anti-MCM2

EPR4120

Abcam, ab108935

1:5000

Anti-PCNA

EPR3821

Abcam, ab92552

1:5000

Anti-B-actin

mAbcam 8226

Abcam, ab8226

1:5000

2.4.6 Immunocytochemistry

The level and intensity of the expression of proliferation markers like MCM2,
PCNA and Ki67 were determined by immunocytochemistry which was performed as
described below. Sections of human tonsil were included in each batch as controls:

1. The slide sections were incubated at 60°C in dry oven for 24 hours, dewaxed for
10 minutes each in xylene I and II and dehydrated in ascending concentration of
ethanol (70, 90 and 100%) respectively.
2. The slides were incubated in 0.5% H2O2 in methanol to prevent endogenous tissue
peroxidase activity and nonspecific background staining.
3. Slides were washed in water. For the antigen retrieval, tonsil sections were boiled
in the citrate buffer for 10 minutes. However, the sections of cultured cells were
more delicate and therefore were incubated in hot buffer (40-50°C) till buffer
cooled down.
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4. The slides were blocked in 200 μl of 5% BSA in tris buffer saline (1XTBST) in
humidified chamber for 2 hours in order to eliminate nonspecific binding.
5. The slides were washed in 1XTBST (3 times for 10 minutes each) and incubated
in 200 μl of the diluted primary antibodies for MCM2 or PCNA or Ki67 in 1%
BSA and incubated at 4°C in humidified chamber (Table 2.4).
6. Sections were washed 3 times for 10 minutes each in wash buffer. The slides were
incubated in 200 μl of 2o antibody, either anti-mouse or anti-rabbit diluted in
1XTBST at 1:200 in humidified chamber at room temperature
7. Sections were washed and then ABC, DAB and H&E counter staining were
performed as described in section 2.2.2, step 9-12.

Table 2.4: Primary antibodies used in immunocytochemistry as follows:
Antibody
Anti-MCM2

Clone
EPR4120

Cat. Number
Abcam, ab108935

Incubation time
2 hours

Dilution
1:100

Anti-PCNA

EPR3821

Abcam, ab92552

2 hours

1:250

Anti-Ki67

SP6

Abcam, ab16667

overnight

1:1000

2.4.7 Microarray analysis

In an attempt to understand the mechanisms involved in EBER1 induced
proliferation, the Commercially available TaqMan® Array 96–Well Plate Human lL-10
Pathway array was used on the BJAB cell line. For each well of the microarray, 60 ng
of cDNA was used. The cDNA and Master Mix were combined in microcentrifuge tube
as follows:
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cDNA sample + nuclease free water

10 µL

Master Mix

10 µL

Total volume

20 µL

The tube was vortexed to mix the contents thoroughly and centrifuged briefly to
collect the contents at the bottom of the tube. For preparing the TaqMan® Array Plate,
the plate package was removed and centrifuged briefly. 20 µL of cDNA Master Mix per
well was added to the appropriate wells of the plate. The plate was sealed with
MicroAmp™ Optical Adhesive Film, centrifuged briefly to collect the contents to the
bottom of the wells and placed in QuantStudioTM 7 Flex Real-Time PCR System
(Applied Biosystems, Germany). The annealing temperature was set up at 60°C. The
relative quantification was calculated by QuantStudioTM 7 Flex Real-Time PCR program.
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Chapter 3: Results
3.1 Checking for EBER1 expression in stably transfected cells

EBER1 expression in the immortalized 293T, Jurkat and BJAB cells was achieved
by transfecting the cells with the Hebo plasmid containing EBER1 sequence. The
expression and the localization of EBER1 in the transfected cell line for 293T, BJAB and
Jurkat were confirmed by RT-PCR and gold standard EBER in situ hybridization (EBERISH).

To confirm the efficacy of plasmid expressing EBER1, RNA was isolated from
the stably transfected cell lines using TRIzol reagent and treated with DNasel to eliminate
any DNA contamination, followed by reverse transcription using hexamer and A-MLV
reverse transcriptase. To conﬁrm the genomic DNA absence, prior to reverse transcription,
PCR was performed on the DNaseI treated samples using the house keeping gene GAPDH
primers (Figure 3.1 A). After confirmation of the absence of DNA contamination, RTPCR was performed on the cDNA samples. The EBER1 transfected cells and the B95-8
were positive for EBER1 expression and the controls were clearly negative (Figure 3.1
B). GAPDH was used as internal control for reverse transcription (Figure 3.1 C).

The results of EBER-ISH using DAB staining showed the presence of EBER1 in
the nucleus of EBER1 transfected cell lines (Figures 3.2, 3.3 and 3.4). The signal however
was weaker than B95-8 cells used as positive control (Figure 3.2). As shown in the figure
3.2, no staining was seen in pHebo transfected 293T cells or when using sense probe,
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confirming that the signals seen in EBER1 transfected cells were specific. Similar results
were seen with EBER1 transfected BJAB cells (Figure 3.3) and Jurkat cells (Figure 3.4).
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Figure 3.1: Checking for EBER1 expression in EBER1 and pHebo transfected cells. (A)
PCR for GAPDH on DNase treated RNA (prior to reverse transcription) confirmed that
there was no contaminating DNA. (B) PCR for EBER1 in cDNA indicated that EBER1
transfected Jurkat (J-ER1), BJAB (B-ER1) and 293T (293T-ER1) all expressed EBER1.
Control (pHebo plasmid only) of these cell lines were clearly EBER1 negative. (C)
GAPDH was however expressed in all cell lines. B95-8 was used as positive control.
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Figure 3.2: EBER1 is expressed in stably transfected cell line 293T and B95-8. EBER1
expression was detected by EBER-ISH in EBER1 transfected cell lines and EBV
positive B95-8. However, no signal was seen in control cells (293T-Hebo). Nucleus
was stained with EBER1 giving positive brown signal with the anti-sense probe (left
panel). No staining was observed with the sense probe (right panel).
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Figure 3.3: EBER1 is expressed in stably transfected BJAB cell line. EBER1 expression
detected by EBER-ISH in the stably EBER1 transfected cell line (left panel), but not in
pHebo control or when using sense probe.
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Figure 3.4: EBER1 is expressed in stably transfected Jurkat cell line. EBER1 expression
detected by EBER-ISH in the stably EBER1 transfected cell line (left panel), but not in
pHebo control or when using sense probe.
3.2 Proliferation activity of EBER1 expressing cells

We have hypothesized that EBER1 expressing cells have the ability to proliferate
more compared to the control cells. To study the proliferation function of EBER1, stably
transfected EBER1 cell lines and the control plasmid (Hebo) cells were plated onto a 24well plate and cell count was quantified each day for 6 days using trypan blue exclusion
assay.
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Figure 3.5 shows that after 24 hours of plating, the cell numbers for EBER1
expressing cells and control remained similar. However, by days 2-4, EBER1 expressing
cells started to show a higher proliferation rate compared to the control cells and this was
statistically significant (Figure 3.5). The pattern of proliferation was not uniform for all
cells. For example, epithelial cells (293T) reached 100% confluency by day 4-5 and were
in the stationary phase. Interestingly, this condition did not limit the 293T-ER1 cells from
proliferating more than the pHebo transfected control cells (Figure 3.5 A). As in the case
of the suspension cells (BJAB and Jurkat), we noticed that even though there was gradual
depletion of the growth factors and higher saturation densities in the culture, EBER1
expressing cells were growing at higher proliferation rate (Figure 3.5 B and C). By day 6
of culture, the difference in the proliferation rate between EBER1 transfected cells (BER1 and J-ER1) and their respective pHebo control cells was very pronounced and
obvious.
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Figure 3.5: Comparison of proliferation between pHebo control and EBER1 expressing cells.
The EBER1 expressing cells exhibited an increase in growth compared to control cells
transfected with pHebo plasmid. Each time point was counted four times and three
independent experiments were carried out. The data presents the mean and standard error of
the mean (SEMs).
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3.3 Analysis of metabolic activity of EBER1 expressing cells

Proliferation activity can be determined by trypan blue exclusion assay or by
measuring the metabolic activity of cellular enzymes. Metabolic activity is regulated by
the pathways of signaling that control cell proliferation. To determine the metabolic
activity in the EBER1 expressing cells, quantitation of ATP activity was used.
Commercially available Cell Titre-Glo viability kit was used to estimate the ATP activity
which was based on the viability of the cultured cells. Following the manufacturer’s
protocol, 100 μl of the EBER1 transfected cell lines and control (suspension
cells~8000/well, adherent cells ~2500/well) were plated in 96-well plates and incubated
at 37°C in a cell-culture incubator for time points ranging from 24 to 96 hours. The time
course experiments were performed for each cell line to determine the optimal period of
culture that should be used for the subsequent assays on ATP activity measurements. This
was important to avoid overgrowth and cell death which could influence ATP activity.
For suspension cells, our data from these experiments showed that after 72 and 96 hours
of plating, BJAB-ER1 and Jurkat-ER1 proliferated more than the control cell lines.
However, culturing cells beyond these times triggered the cells to start dying. According
to our results, the levels of ATP activity in cells transfected with EBER1 was significantly
higher than the control cell lines (Figure 3.6). For epithelial cells (293T-ER1) which had
optimal culture time of 48 hours, the ATP activity and hence, cell proliferation was three
times higher than the corresponding control (293T-pHebo) cells significantly (Figure 3.6).
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Figure 3.6: Comparisons of proliferation based on ATP activity between the cells
transfected with EBER1 and control (Hebo). The data plotted as a mean of the three
independent experiments.
3.4 Growth rate of EBER1 expressing cells in serum deprived condition

We investigated the proliferation of EBER1 expressing cells along with the
corresponding controls under serum deprivation. For BJAB and Jurkat cells, the cells were
washed and seeded onto 24 well plates with serum free medium. The growth of cells was
monitored daily for 6 days. However, for adherent cells, the cells were seeded with serum
containing growth media and incubated for 24 hours to allow the cells to adhere. The
media was then replaced with serum free media. The cell viability was counted for 6 days
using the trypan blue exclusion assay.
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The three different cell lines, 293T, BJAB and Jurkat, behaved differently in
response to serum deprivation. Surprisingly, 293T cells continued to grow for several days
even in the absence of serum. Even under these conditions, there was a clear difference
between EBER1 transfected cells and pHebo controls. 293T-ER1 proliferated at a higher
rate compared to 293T-Hebo cells (Figure 3.7 A). However, by day 5 both cell lines started
dying due to the lack of nutrients in the media. One possible explanation why 293T cells
did not start dying from day 1 of serum depletion is that these cells were initially incubated
for 24 hours in growth media to allow them to adhere and settle. Although the growth
media was replaced with the serum depleted media, it is very likely that some of the
growth media was still present to allow survival and proliferation of these highly resistant
cells.

By contrast, the suspension cells (BJAB and Jurkat) were much more susceptible
and started dying within first day of serum deprivation. For both cell lines however,
EBER1 transfected cells proved to be more resistance to cell death compared to pHebo
transfected control cells (Figure 3.7 B and C). These observations suggest that EBER1
may have the capacity to resist apoptosis and proliferate even under stressed conditions,
as in the case of serum deprived state.
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Figure 3.7: The growth of cells transfected with EBER1 compared to controls in serum free
media condition. (A) Growth curves of 293T cells (293T-ER1 and 293T-Hebo). (B) Growth
curves of BJAB cells (B-ER1 and B-Hebo). (C) Growth curves of Jurkat cells (J-ER1 and JHebo). The data are expressed as mean ± SD of three independent experiments.
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3.5 Colony formation of EBER1 expressing cells: soft agar assay

In support of our hypothesis that EBER1 expressing cells have a huge rate of
proliferation in culture, we wanted to determine the effect of EBER1 on anchorage
independent growth and it is ability to induce cell proliferation and colony formation in
soft agar.

For this aim, we plated 293T cells in soft agar as described in our previous report
(Ahmed et al., 2015). For the negative control, PBS was added to the wells instead of
cells. Within five days of incubation, under the light microscope, we were able to see that
the size and the colony numbers were almost similar in both transfected cells (Figure 3.8
A). However, by day twelve, the size and number of colonies in EBER1 expressing cells
had gone up more than the control (Figure 3.8 B).
After eighteen days of incubation, further increase in the size and number of
colonies in 293T-ER1 cells was observed, which was now visible by the naked eye. By
contrast, most of the cells in the pHebo control showed much smaller and fewer colonies
(Figure 3.9). These observations suggest that EBER1 expression has a signiﬁcant effect
on anchorage independent growth in immortalized epithelial cells.
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Figure 3.8: 293T-EBER1 and control cells were grown in soft agar and allowed to form
colonies for up to 12 days. (A) The 293T Hebo and ER1 showed similar number and size
of colonies on day five of culture. (B) The colony size and number of 293T-ER1
increased more than 293T-Hebo by day twelve.
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Figure 3.9: 293T-EBER1 and control cells were grown in soft agar and allowed to form
colonies for up to 18 days. Significant difference in the size and number of colonies was
observed in 293T-ER1 after bromophenol blue staining on 18th day of post culturing.
No colonies were observed in the PBS control group (negative control) (not shown).
3.6 Expression of proliferation markers in EBER1 expressing cells: qRT-PCR

The data from our analysis of cell proliferation, metabolic activity and colony
formation studies clearly indicated that EBER1 provided a proliferative advantage to
EBER1 transfected cells. To understand what could be driving proliferation of EBER1
transfected cells, we looked for the expression of three well known markers of cell
proliferation namely, MCM2, PCNA and Ki67. We used SYBR green qRT-PCR to study
the relative expression of these proliferation markers at mRNA level. Expression was
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measured in two cell lines, EBER1 transfected BJAB and Jurkat, together with pHebotransfected controls.

Both EBER1 transfected cell lines (BJAB and Jurkat) had higher levels of
expression of the proliferation markers compared to their control counterparts
significantly (Figure 3.10). PCNA was overexpressed more than 2.5 fold in BJAB-ER1
cells compared to the controls. EBER1 also increased mRNA expression of PCNA in
Jurkat cells approximately 1.5 fold (Figure 3.10 A). Similarly, the mRNA expression
levels of MCM2 were significantly higher in both cell lines transfected with EBER1
compared to controls (Figure 3.10 B). We also examined Ki67 expression, which was
found to be approximately 1.5-2.0 fold higher in EBER1 transfected cells and this was
statistically significant (Figure 3.10 C).
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Figure 3.10: Effects of EBER1 on PCNA, MCM2 and Ki-67 mRNA expression.
qRT-PCR was performed on the cDNA generated from 4μg of the RNA isolated
from BJAB and Jurkat cell lines. Proliferation markers values were normalized to
levels of β-actin mRNA. The data are expressed as mean ± SD of three independent
experiments.
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3.7 Expression of proliferation markers in EBER1 expressing cells: western blot
analysis
Our data has consistently shown a higher rate of proliferation of EBER1
transfected cells compared to controls. Moreover, based on our qRT-PCR analysis,
proliferation markers PCNA, MCM2 and Ki67 were up regulated at RNA level. To further
understand the mechanism of cell proliferation at the cell cycle level, we looked at the
expression of these markers at protein level.

We determined the level of expression of these markers by western blot using
antibodies specific to these markers. Housekeeping gene β-actin was used as an internal
control to check loading consistency. The Western blot analysis revealed that both PCNA
and MCM2 were expressed at higher levels in EBER1 expressing cells compared to
controls. Image J was used to quantify the difference in the expression profile. Indeed, in
all three cell lines, 293T, BJAB and Jurkat, EBER1 transfected cells had higher levels of
PCNA and MCM2 than the pHebo transfected controls (Figure 3.11).

The level of expression of PCNA and MCM2 was not uniform in all the cells. For
example, EBER1 transfected BJAB cells expressed the highest level of PCNA (2-fold
higher than control) whilst 293T and Jurkat cells expressed PCNA at approximately 1.5
times than observed in their controls (Figure 3.11 A2). We also found that, in EBER1
expressing BJAB and Jurkat cells, the expression level of MCM2 were elevated to 1.6 and
2.5 fold compared to controls, respectively. In 293T cells however, MCM2 level was only
moderately increased (10%) (Figure 3.11 B).
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Figure 3.11: Western blots for proliferation markers (PCNA and MCM2) on EBER1
expressing cells and control. β-actin was used as loading control. (A1) The level of PCNA
protein was higher in all EBER1 transfected cells compared to the control. (A2) Using
Image J program, the level was estimated to be 1.5-2.0-fold. Similar observations were
seen for MCM2 expression (B1 and B2).
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3.8 Expression of proliferation markers in EBER1 expressing cells:
immunocytochemistry

Since proliferation markers PCNA and MCM2 showed differences in their
expression between cells with and without EBER1 by western blot analysis. We
performed immunocytochemistry, to see whether this difference in expression could also
be observed by this approach. The paraffin sections of EBER1 transfected and pHebo
transfected cells embedded in agrose were used for this purpose. Sections of human tonsils
were used to optimize the staining for PCNA, Ki67 and MCM2. In our study, the sections
of tonsil gave positive staining for all three markers. As expected, the highly proliferating
cells in the germinal centers expressed the highest level of these proliferation markers
(Figure 3.12 A1). The negative controls remained negative throughout the experiments as
expected (Figure 3.12 A2).

Ki-67 is a key marker for cellular proliferation and is detected as nuclear staining.
Our results showed that the staining intensity was higher in EBER1 expressing cells
compared to that of the control (Figures 3.13, 3.14, and 3.15, left panel). The highest
signal intensity was observed in the Jurkat-ER1 cells compared to all the EBER1
transfected cell lines (Figure 3.15, left panel).
The expression of PCNA was also recognizably high in all EBER1 expressing
cells compared to pHebo transfected controls (Figures 3.13, 3.14 and 3.15, middle panel).
Nuclear immune staining for MCM2 showed high expression in the EBER1 expressing
cells compared to the controls, except in the epithelial 293T cells where this distinction
was very less. Both EBER1 transfected and pHebo transfected 293T cells expressed high
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levels of MCM2 (Figure 3.13, right panel). From the three different cell lines, the effect
of EBER1 on MCM2 expression was most obvious in BJAB cells (Figure 3.14, right
panel). This was both in terms of staining intensity and the number of cells which were
positive. Overall, our findings indicated that these cellular proliferation markers were
expressed at higher levels, particularly in EBER1 transfected BJAB and Jurkat cells
compared with their controls.
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Figure 3.12: Immunocytochemistry for proliferation marker (PCNA, MCM2 and Ki67) on tonsil. The
higher expression of proliferation markers was seen in the germinal center where the cells were
proliferating and less expression was noticed in the non-germinal center (A1). No staining was seen
in negative control (A2) ruling out non-specific staining possibilities.
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Figure 3.13: Immunocytochemistry for proliferation markers (PCNA, MCM2 and Ki67)
on EBER1 expressing 293T cells. Higher expression of Ki67 and PCNA was observed in
293T-EBER1 compared to the control (left and central panel), however, this difference
was less clear in MCM2 expression (right panel).
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Figure 3.14: Immunocytochemistry for proliferation markers on EBER1 expressing
BJAB cells. Higher expression of Ki67, PCNA and MCM2 was seen in B-EBER1
compared to the control.
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Figure 3.15: Immunocytochemistry for proliferation markers on EBER1 expressing Jurkat
cells. Higher expression of Ki67, PCNA and MCM2 was seen in J-EBER1 compared to the
control.
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3.9 Microarray analysis of EBER1 transfected cells

In an attempt to understand the molecular pathways involved in EBER1 induced
cell proliferation, we used microarray technology to determine which genes were
expressed. Specifically, we used IL-10 microarray plates to determine gene expression
profile in EBER1 transfected BJAB cells. This analysis identified a common set of genes
that were regulated by EBER1 in BJAB transfected cell lines. The association of
modulated genes with biological function revealed several pathways that may be affected
by EBER1 to induce cell cycle and proliferation (Figure 3.16).

Our results showed that more than one pathway, including IL-10 and Toll receptor4 (TLR-4) pathway may be activated by EBER1. Moreover, many genes were activated
in more than one pathway. The genes which were upregulated in the EBER1 transfected
cells where sub-grouped according to their functions. Our analysis indicated that IL-10
was upregulated by EBER1 more than 25-folds. Other highly upregulated genes were
TLR-4, CCND2 and IL1B. Furthermore, IL-10 A and IL-10 B receptors were also
upregulated upto 2 and 3 folds compared to that of the control. Similarly, TYK2, JAK and
STAT3 were also upregulated more than 2-folds. Other related genes that appeared to be
upregulated by EBER1 included, PIK family of genes, NF-ĸB family and MAPK genes.
These genes are thought to be involved in a wide variety of cellular processes, including
proliferation, transcription and inhibition of apoptosis. Interestingly, we also observed the
expression of IL-6 at higher levels in EBER1 transfected cells. IL-6 is well known to
induce proliferation of B-cells (Figure 3.16).
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Figure 3.16: Up-regulation of genes in IL-10 and TLR-4 pathways. (A) Genes which are
expressed 5-40 folds in EBER1 transfected cells compared to controls (pHebo). (B) Genes
upregulated in the IL-10 pathways. (C) Genes up-regulated in the Toll receptor 4 pathway.
(D) The downstream genes of both TLR4 and IL-10 pathways.
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Chapter 4: Discussion
Epstein Barr virus (EBV), which is one of the most common and prolific Gamma
Herpesviruses, infects more than 90% of the human population. EBV infects epithelial
cells and B-lymphocytes and persists for life in memory B cells (Longnecker et al., 2013).
The virus plays a role in several different malignancies of epithelial and lymphoid origin,
as well as in some autoimmune disorders (Okano and Gross, 2012; Vockerodt et al., 2015).
It has been estimated that malignancies triggered by EBV are responsible for causing
~1.8% of cancer deaths (Khan and Hashim, 2014; Cao, 2017), which has increased by
14.6% over a period of last 20 years. Thus, understanding the molecular details of EBVassociated pathologies is crucial for the development of possible interventions (Cohen et
al., 2013). It has been known that EBV undergoes different latency programs in which a
number of viral transcripts are expressed. Epstein-Barr virus encoded RNAs (EBER1 and
EBER2) are two highly abundant transcripts, that are expressed in all forms of viral
latencies (Longnecker et al., 2013).

EBER1 has been shown to be present at 10-fold higher levels in infected cells
compared to EBER2, probably due to the longer half-life of EBER1 (Clarke et al., 1992).
However, it remains poorly understood why EBER1 is expressed in large amounts. It has
been shown that EBER1 stem loop structures have higher affinity towards RNA-protein
interactions (Chavez-Calvillo, Martin, Hamm, & Sztuba-Solinska, 2018). It has also been
reported that EBERs, specifically EBER1, contributes to cell proliferation in EBV
infected cells or EBER1 transfected cells by interacting with a number of cellular proteins
(Clemens, 2006). Moreover, previous studies have suggested that EBER expression may
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stimulate the production of IL-10, leading to cell proliferation (Yang et al., 2004). Thus,
it is plausible that EBER1 could be promoting cell proliferation in the transfected cells via
IL-10 pathway. To understand the role of EBER1 in cell proliferation, we transfected
EBER1 into different cell types, resulting in the generation of EBER1 expressing stable
cell lines. Several different cell lines (293T, BJAB and Jurkat) were transfected with
EBER1 plasmid along with the control plasmid (Hebo). Although all of the EBER1
transfected cells expressed EBER1, the level of expression of EBER1 in these stable cell
lines was lower than the EBV infected B95-8 cells. The lower expression of EBER1 in
the transfected cells could possibly be due to the low plasmid copy number per cell.
Moreover, the absence of viral factors such as EBNA1, that has been shown to enhance
the level of EBER expression, could also result in low EBER1 expression (Owen et al.,
2010; Frappier, 2015).

Our results showed that EBER1 induce proliferation in different cell lines. In our
growth and survival analysis, different growth properties between the EBER1 transfected
cells and controls were observed under growth limiting conditions. Under normal growth
conditions (10% FBS media) the proliferation was more in EBER1 transfected cells than
that of control vector‐transfected cells at the log phase. Similarly, the saturation density
of EBER1 transfected cells was higher than that of controls at the stationary phase. These
findings are consistent with previous studies which showed that proliferation of EBER
expressing epithelial and B cells are higher than control cells (Komano et al., 1999; Wong
et al., 2005; Yamamoto et al., 2000). However, little is known regarding the effect of
EBER1 on the proliferation of T cells. Our study confirmed that EBER1 can also induce
cell proliferation in T cells.
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Furthermore, our results showed that EBER1 transfected cells can withstand serum
deprivation conditions in comparison with control cells. Supporting our findings, EBERs
were shown, in an earlier study, to confer resistance to apoptosis induced by low serum
concentration in B cells (Komano et al., 1999; Yamamoto et al., 2000). Nevertheless, this
has not been shown before in T cell lines. These findings support the notion that EBER1
possesses the ability to promote proliferation and at the same time show resistance to
apoptosis when induced by saturation or serum deprivation. Additionally, our study
demonstrates that EBER1 can promote malignant transformation in transformed 293T
cells by the anchorage independent growth. Our results consistently showed the ability of
EBER1 to induce proliferation in the epithelial, B and T-cells and enhance the
transformation of immortalized epithelial cells. However, the molecular details behind the
increase in cell number and subsequent increased proliferation are unknown.

4.1 Metabolic activity of the EBER1 expressing cells compared to control

Interestingly, nutrients via pathways that generate ATP molecules produce all the
components necessary to duplicate the cell mass and cell division. Nutrient uptake is
controlled by cell signaling pathways that also regulate cell proliferation and growth
(Deberardinis, Sayed, Ditsworth, & Thompson, 2008; Vander Heiden, Cantley, &
Thompson, 2009). These pathways of cell signaling play a role in the development of
cancer, and their inappropriate activation in cancer is accompanied by an increase in
nutrient uptake that has been described as a characteristic feature of malignant cells
(Vander Heiden et al., 2009). Furthermore, ATP production plays a role at the restriction
checkpoint and enhanced activation of cyclin/CDK for cell cycle regulation (Levine &
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Puzio-Kuter, 2010). As a result, there is a linear correlation between ATP activity and cell
proliferation (Vander Heiden et al., 2011). Our findings suggested that EBER1 expression
may support increased ATP activity of the immortalized cells to increase cell proliferation.
Our findings showed that EBER1 expression affected the metabolic activity of epithelial
cells. These cells had a threefold higher metabolic activity compared to the control.
Additionally, EBER1 expressing B and T cells also showed significantly increased
metabolic activity compared to the controls.

4.2 The role of EBER1 at the level of cell cycle progression

To further understand the proliferation abilities of EBER1 transfected cells, we
looked into the expression profile of a number of cellular proliferation markers. We
studied this by examining the protein and RNA levels of selected proliferation markers in
EBER1 transfected cells. Several cell proliferation markers have been identified which
are present in growing or dividing cells. These markers, for example, MCM2, Ki67 and
PCNA, serve as an indicators of cell division during different stages of cell cycle and have
been used as prognostic markers in cancer diagnosis (Bologna-Molina, Mosqueda-Taylor,
Molina-Frechero, Mori-Estevez, & Sanchez-Acuna, 2013). However, there is no study till
date showing the relation between EBER1 and the proliferation markers. Our study
showed for the first time that EBER1 has some effect on the expression of proliferation
markers, MCM2, Ki67, and PCNA. Our results with these three potential proliferation
markers, MCM2, Ki67 and PCNA, indicated that these markers are upregulated in EBER1
transfected cells compared to controls. We quantified the MCM2 gene expression by qRTPCR which showed that MCM2 expression is upregulated in EBER1 expressing BJAB
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and Jurkat cells, almost 2-fold compared to controls. The level of MCM2 protein
expression observed by immunocytochemistry and western blot was also higher in BJAB
and Jurkat cells transfected with EBER1 compared to that of the controls. Studies have
indicated that the importance of MCM2 (Minichromosome Maintenance Protein 2) is for
initiating the DNA replication of eukaryotic genome once per cycle. Higher expression of
MCM2 is associated with several clinical pathological parameters, such as advanced
tumor grade, poor prognosis, in breast cancer and colon cancer (Juríková, Danihel, Polák,
& Varga, 2016). Similarly, our results showed elevated expression at mRNA and protein
levels for PCNA and Ki67 in the B, T and epithelial cells transfected with EBER1. Both
of these proliferation markers are expressed in G1, S, G2 and M phase and excluded in
Go (Juríková et al., 2016). Although the exact molecular pathway by which Ki67 acts is
not well understood, it is frequently used as tumor marker in the drug discovery field,
pathology research and diagnostic studies (Bologna-Molina et al., 2013; Juríková et al.,
2016). However, PCNA, (proliferating cell nuclear antigen) a non-histone protein is
employed to repair the damaged and replicated DNA and act as an accessory for RNA
polymerase alpha. PCNA as a marker of cell proliferation is heavily expressed for a long
time in G1 and S phase where the cell goes to proliferation phase (Juríková et al., 2016;
Kelman, 1997).

Overall, our result showed that the expression of cell proliferation markers such as
MCM2, Ki67 and PCNA was increased in the EBER1 transfected cells. This upregulation
of proliferation markers could be due to EBER1 expressing cells regulating certain genes
to modulate the downstream pathways and activating cell cycle by these proliferation
markers. However, these observations need further investigation.
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4.3 Mechanisms of cell proliferation could be triggered by EBER1

A number of previous studies have shown that the expression of interleukin-10
(IL-10) improves growth of Burkitt’s lymphoma cells in response to EBER presence
(Gregorovic et al., 2011). To further understand the mechanism of IL-10 induction, we
used a commercially available microarray kit to look at the genes in the proliferation
pathway which induce IL-10. Our results showed that, in EBER1 expressing BJAB cells,
IL-10 was up-regulated along with other genes, as compared to the control. This result,
supports the previous findings showed that EBER expression can enhance the production
of autocrine growth factors like IL-10 (Kitagawa et al., 2000). However, we also observed
the induction of JAK/STAT and PI3K pathways in the EBER1 transfected BJAB cells.
There has been studies which reported that activation of JAK/STAT and PI3K pathways
promote the expression of genes involved in cell cycle regulation (Vaysberg, Lambert,
Krams, & Martinez, 2009). Our results suggested that EBER1 may play a role to activate
JAK/STAT and PI3K pathway in EBER1 transfected cells and regulate the cell cycle
progression. Moreover, in the EBER1 transfected cells, we observed that the downstream
genes such as BCL2L1, CCND1, 2 and 3 and IL-6 were triggered, and therefore may
contribute to anti-apoptotic, cell-cycle progression and

proliferation of B cells,

respectively (Murray, 2007). A recent in vivo study showed that EBERs interact with
TLR-3 to produce cytokines such as IL-6 and IL-10 (Li et al., 2015). Studies also have
reported that depending on the cell type, EBERs stimulate production of cytokines, such
as IL-10 and anti-apoptotic signals such as BCL-2 (Komano et al., 1999; Tycowski et al.,
2015).
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Chapter 5: Conclusion
In this study, we focused on understanding the role of EBER1 in EBV
pathogenesis. Since EBV is known to infect different types of cells, we transfected EBER1
into three different cell types, namely 293T (epithelial cells), BJAB (B cells) and Jurkat
(T cells), to understand the role of EBER1 in cell proliferation. Our results can be
summarized as follows:

1) EBER1 has the ability to induce proliferation in epithelial, B and T cells, which
was evident through high ATP activity in the transfected cells compared to the
controls. Similarly, the cell counting assays also showed that EBER1 transfected
cells had higher cell counts compared to the controls, despite been grown under
similar conditions. Furthermore, EBER1 expression alone has signiﬁcant effect on
anchorage independent growth in immortalized epithelial cells by increasing in the
size and number of colonies being formed.
2) EBER1 expressing cells showed higher production of proliferation markers such
as Ki67, PCNA and MCM2, which are known to play a role in the cell cycle
progression and subsequent increase in proliferation.
3) The microarray analysis showed that EBER1 transfected BJAB cells had increased
levels of pro-inflammatory cytokines, anti-apoptotic and cell proliferation signals
via IL10 pathway. Our future studies will be focused on analyzing the genes
upregulated in our microarray analysis and further dissect out the possible
mechanism of induction of various cytokines by EBER1 transfected cells.
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Appendix
Freezing Media
•

Adherent or non-adherent cell line: 10% Dimethyl sulfoxide (DMSO) in DMEM
or RPMI

Hybridization Buffer
•

Formamide deionized (Sigma, Cat# F9037)

2.5 ml

•

Dextran sulphate (Sigma, Cat# D8906)

1 ml

•

20X SSC (saline Na3C6H5O7 (1L, pH 7.0),

500 µl

NaCl (175.3 g, 3 M), Na3C6H5O7 (800 ml), ddH2O (800 ml))
•

Tris-HCl (2 M, pH 7.5)

125 µl

•

ddH2O

875 µl

6x loading Buffer
•

6 g SDS, 5.91 g Trizma base, 9 ml β-mercaptoethanol, 48 ml glycerol, 30 mg
bromophenol blue, volume was made upto 100 ml in dH2O

RIPA Buffer
•

50 mM Tris (pH 7.4), 150 mM NaCl, 1% Triton X-100, 1% Sodium
deoxycholate, 0.1% SDS, volume made up in dH2O and filter sterilized

10X Running Buffer
•

10 g SDS, 30.2 g Trizma base, 144 g glycine, volume was made up to 1000 ml in
dH2O).
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SDS Gel Recipe
10% Resolving Gel

4% Stacking Gel

ddH2O:

8 ml

ddH2O:

6.1 ml

Tris pH 8.8:

5 ml

Tris pH 6.8:

2.5 ml

30% Acrylamide: 6.7 ml

30% Acrylamide: 1.34 ml

10% SDS:

200 μl

10% SDS:

100 μl

10% APS:

200 μl

10% APS:

100 μl

TEMED:

20 μl

TEMED:

20 μl

10X transfer Buffer
•

45.4 g Trizma base, 216 g glycine, volume was made upto 1000 ml in dH2O.
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